Chapter 14 - Whipple's disease of the central nervous system
Introduction
George Whipple initially reported the disease bearing his name in 1907, in which he described a 36-year-old male medical missionary with an illness characterized by weight loss and intractable diarrhea (Whipple, 1907). However, extragastrointestinal manifestations were recognized from the first descriptions of this illness as well as in subsequent reports. Whipple's initial observations included all of the essential bowel manifestations of the disease, with pathological features of lipid degeneration involving the intestinal mucosa, and involvement of the mesenteric lymph nodes with argyrophilic rod-shaped microorganisms; this initial description included the name “intestinal lipodystrophy.” Whipple also recognized the systemic features of the disease such as polyarthritis, polyserositis, endocarditis, and lymphadenopathy. It was later established that the macrophages involved by this disease contained periodic acid–Schiff (PAS)-positive material, indicative of the presence of glycoprotein. Later, electron microscopic investigations showed that the PAS-positive material consisted of curvilinear-shaped bacilli (Chears and Ashworth, 1961, Yardley and Hendrix, 1961).
Section snippets
Etiology and Epidemiology
Identification and characterization of the Whipple's disease agent were performed by molecular techniques using ribosomal RNA sequences amplified from the duodenal tissue of a patient with Whipple's disease (Relman et al., 1992). This sequence was subsequently detected in tissues from patients identified with Whipple's disease, but in none of the patients without the disorder (Relman et al., 1992). The bacterium was discovered to be a gram-positive actinomycete which, at the time, was not
General features
Whipple's disease remains a rare disorder. Although no incidence data are available, at least 1000 cases have been reported (Fenollar et al., 2007). It can occur in all ages and races, but white middle-aged men have been the predominant group affected. The primary systemic symptoms are weight loss, diarrhea, and abdominal pain. Other systemic symptoms, including serositis, arthritis, lymphadenopathy, and fever, have been identified; cardiac involvement is also well recognized (Enzinger and
Neuroimaging
Neuroimaging abnormalities are thought to occur in at least half of the patients with CNS Whipple's disease (Louis et al., 1996). Magnetic resonance imaging (MRI) of the brain is the most sensitive neuroimaging study and has most commonly shown focal increased T2 or fluid-attenuated inversion recovery (FLAIR) signal involving the hypothalamus, uncus, and medial temporal lobes (Fig. 14.1A) (Adams et al., 1987). Bright T2 and FLAIR signal abnormalities may also be prominent in the cerebellar
Neuropathology
The first descriptions of pathological changes in the brains of patients with Whipple's disease date back to 1960, when descriptions of presumed neurologically asymptomatic individuals with granular ependymitis were published (Sieracki et al., 1960). Pathological studies were subsequently published, emphasizing the involvement of brainstem and basal brain structures which paralleled the clinical symptomatology (Lampert et al., 1962, Halperin et al., 1982); the neuropathology of a nodular
Treatment
Intravenous penicillin, followed by a prolonged course of oral trimethoprim-sulfamethoxazole, had been the regimen of choice in the treatment of CNS Whipple's disease. Tetracycline has also been utilized, but is associated with a high incidence of relapse of disease (Marth and Raoult, 2003). The current treatment recommendation for CNS disease is ceftriaxone 2 grams intravenously every 12 hours for 2 weeks followed by oral trimethoprim-sulfamethoxazole (one tablet double strength twice daily)
References (41)
- et al.
Electron microscopic study of the intestinal mucosa in Whipple's disease. Demonstration of encapsulated bacilliform bodies in the lesion
Gastroenterology
(1961) - et al.
Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients
Mayo Clin Proc
(1988) - et al.
Whipple's disease
Lancet
(2003) - et al.
Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid
Gastroenterology
(1997) - et al.
Whipple's disease confined to the central nervous system
Ann Neurol
(1987) - et al.
Oculo-facial-skeletal myorhythmia in Whipple disease: treatment with ceftriaxone
Ann Intern Med
(1990) - et al.
Whipple's disease mimicking progressive supranuclear palsy: the diagnostic value of eye movement recording
J Neurol Neurosurg Psychiatry
(1999) Whipple disease
- et al.
Cervical myelopathy caused by Whipple's disease
Neurology
(1998) - et al.
Isolated CNS Whipple disease with a variant of oculofacial-skeletal myorhythmia (OFSM)
Neurology
(2007)
Synovial fluid polymerase chain reaction as an aid to the diagnosis of central nervous system Whipple's disease
Ann Neurol
Whipple's disease: a review of the literature and report of fifteen patients
Virchows Arch Pathol Anat Physiol Klin Med
Whipple's disease
N Engl J Med
Cerebral Whipple's disease with negative jejunal histology
N Engl J Med
Whipple's disease with predominantly neuroophthalmic manifestations
Ann Neurol
Cranial computed tomography in Whipple's disease
J Comput Assist Tomogr
Whipple disease of the nervous system
Neurology
Cerebral Whipple's disease
Diagnosis by brain biopsy. Am J Clin Pathol
Cerebral ocular Whipple's disease: a 62-year odyssey from death to diagnosis
Neurology
Involvement of central nervous system in Whipple's disease
Neurology
Cited by (3)
Diagnostic Pathology: Neuropathology
2017, Diagnostic Pathology: NeuropathologyWhipple's disease
2014, Infections of the Central Nervous System: Fourth EditionClinical application of cerebrospinal fluid testing in central nervous system infectious diseases
2013, Chinese Journal of Contemporary Neurology and Neurosurgery